Markets:

Overview

News

Currencies

International

Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

337.81 +17.44 (+5.44%)

Streaming Delayed Price Updated: 10:04 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 Next >

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

May 21, 2025

Via The Motley Fool

Topics Economy Law Enforcement

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

May 14, 2025

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

May 13, 2025

From BeiGene, Ltd.

Via Business Wire

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Earnings Scheduled For May 14, 2025 ↗

May 14, 2025

Via Benzinga

Earnings Preview: BeiGene ↗

May 13, 2025

Via Benzinga

Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat ↗

May 07, 2025

BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance.

Via Benzinga

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

May 07, 2025

From BeiGene, Ltd.

Via Business Wire

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

April 29, 2025

From BeiGene, Ltd.

Via Business Wire

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back ↗

April 26, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial ↗

April 23, 2025

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Via Stocktwits

Why Is Summit Therapeutics Stock Soaring On Wednesday? ↗

April 23, 2025

Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.

Via Benzinga

BeiGene to Announce First Quarter 2025 Financial Results on May 7

April 17, 2025

From BeiGene, Ltd.

Via Business Wire

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗

April 11, 2025

Via Benzinga

Forecasting The Future: 4 Analyst Projections For BeiGene ↗

April 10, 2025

Via Benzinga

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

April 07, 2025

Via Benzinga

BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit ↗

April 03, 2025

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

Via Benzinga

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

April 03, 2025

From BeiGene, Ltd.

Via Business Wire

Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket ↗

March 27, 2025

Via Benzinga

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer ↗

March 26, 2025

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans.

Via Benzinga

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors ↗

March 18, 2025

Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.

Via Benzinga

Earnings Scheduled For March 7, 2025 ↗

March 07, 2025

Via Benzinga

China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer ↗

March 04, 2025

BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1-positive patients.

Via Benzinga

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

March 04, 2025

From BeiGene, Ltd.

Via Business Wire

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

February 27, 2025

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present at Upcoming Investor Conferences

February 25, 2025

From BeiGene

Via Business Wire

Alibaba, Super Micro Computer And XPeng Are Among Top 10 Large Cap Gainers Last Week (Feb 17-Feb 21): Are The Others In Your Portfolio? ↗

February 23, 2025

Top performing large-cap stocks in the last week: Unity, Super Micro Computer, Alibaba, FTAI Aviation, STMicroelectronics, XPeng, Analog Devices, BeiGene, Tencent Music, Microchip Technology.

Via Benzinga

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

February 13, 2025

From BeiGene, Ltd.

Via Business Wire

ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism ↗

January 29, 2025

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

Via Stocktwits

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.